Recent HIV/AIDS News from NIAID and FDA

May 9, 2013: NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies “A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research.” Read the NIAID press release.   May 13, 2013: FDA Announces Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research “On June 14, 2013, as part of the Patient-Focused Drug Development initiative intended to enhance patient input, FDA will be hosting a public meeting on human immunodeficiency virus (HIV) Patient-Focused Drug Development and HIV Cure Research. FDA is interested in obtaining patient input on the impact of HIV on daily life and currently available therapies to treat the condition (topic 1), and patients’ views on issues related to HIV cure research (topic 2).”  Read the FDA meeting announcement. May 14, 2013: Regulatory Officials Informed of HVTN 503 HIV Vaccine Trial Findings “Officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the NIAID-funded HIV Vaccine Trials Network (HVTN), and study investigators have recently informed the appropriate regulatory authorities in South Africa and the United States of findings from their follow-up analysis o...